Show simple item record

A case of fatal ephedra intake associated with lipofuscin accumulation, caspase activation and cleavage of myofibrillary proteins

dc.contributor.authorChen‐scarabelli, Carolen_US
dc.contributor.authorHughes, Siân E.en_US
dc.contributor.authorLandon, Giorgioen_US
dc.contributor.authorRowley, Peteren_US
dc.contributor.authorAllebban, Zuhairen_US
dc.contributor.authorLawson, Noelen_US
dc.contributor.authorSaravolatz, Louisen_US
dc.contributor.authorGardin, Juliusen_US
dc.contributor.authorLatchman, Daviden_US
dc.contributor.authorScarabelli, Tiziano M.en_US
dc.date.accessioned2014-02-11T17:57:19Z
dc.date.available2014-02-11T17:57:19Z
dc.date.issued2005-08en_US
dc.identifier.citationChen‐scarabelli, Carol ; Hughes, Siân E. ; Landon, Giorgio; Rowley, Peter; Allebban, Zuhair; Lawson, Noel; Saravolatz, Louis; Gardin, Julius; Latchman, David; Scarabelli, Tiziano M. (2005). "A case of fatal ephedra intake associated with lipofuscin accumulation, caspase activation and cleavage of myofibrillary proteins." European Journal of Heart Failure 7(5): 927-930. <http://hdl.handle.net/2027.42/102708>en_US
dc.identifier.issn1388-9842en_US
dc.identifier.issn1879-0844en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/102708
dc.description.abstractEphedra, a herb reported to suppress appetite and stimulate the sympathetic nervous system as well as cardiac performance, has recently been related to several adverse events, including seizure, stroke, hypertension, myocardial infarction, and sudden death. Here, we describe the case of a 45‐year‐old woman who died of cardiovascular collapse while taking ephedra. Tissue analysis revealed non‐specific degenerative alterations in the myocardium (lipofuscin accumulation, basophilic degeneration and vacuolation of myocytes, as well as myofibrillary loss), associated with myocyte apoptosis, caspase activation, and extensive cleavage of miofibrillary proteins α‐actin, α‐actinin, and cardiac troponin T. Healthcare professionals are therefore urged to warn their patients about the risk of serious adverse effects, which may follow ephedra intake.en_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherCleavage of Myofibrillary Proteinsen_US
dc.subject.otherLipofuscin Accumulationen_US
dc.subject.otherEphedraen_US
dc.subject.otherCaspase Activationen_US
dc.titleA case of fatal ephedra intake associated with lipofuscin accumulation, caspase activation and cleavage of myofibrillary proteinsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelCardiovascular Medicineen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid16054866en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/102708/1/ejhf2004-09-012.pdf
dc.identifier.doi10.1016/j.ejheart.2004.09.012en_US
dc.identifier.sourceEuropean Journal of Heart Failureen_US
dc.identifier.citedreferenceTorpy J.M. Ephedra and ephedrine JAMA 2003 289 12 1590en_US
dc.identifier.citedreferenceWooltorton E. Sibbald B. Ephedra/ephedrine: cardiovascular and CNS effects CMAJ 2002 (Mar. 5) 166 5en_US
dc.identifier.citedreferenceSamenuk D. Link M.S. Homoud M.K. et al. Adverse cardiovascular events temporally associated with Ma Huang, an herbal source of ephedrine Mayo Clin. Proc. 2002 77 12 16en_US
dc.identifier.citedreferenceXenadrin Product Info (Cytodyne Technologies) Available at http://www.musclesurf.com. Accessed 5/12/03en_US
dc.identifier.citedreferenceHaller C.A. Benowitz N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids N. Engl. J. Med. 2000 343 25 1833 1838en_US
dc.identifier.citedreferenceBent S. Toedt T.N. Odden M.C. Shlipak M.G. The relative safety of ephedra compared with other herbal products Ann. Intern. Med. 2003 138 468 471en_US
dc.identifier.citedreferenceScarabelli T.M. Pasini E. Ferrari G. et al. Warm blood cardioplegic arrest induces mitochondrial‐mediated cardiomyocyte apoptosis associated with increased urocortin expression in viable cells J. Thorac. Cardiovasc. Surg. 2004 128 364 371en_US
dc.identifier.citedreferenceCommunal C. Sumandea M. de Tombe P. Narula J. Solaro R.J. Hajjar R.J. Functional consequences of caspase activation in cardiac myocytes Proc. Natl. Acad. Sci. U. S. A. 2002 99 9 6252 6256en_US
dc.identifier.citedreferenceGreen D.R. Apoptotic pathways: the roads to ruin Cell 1998 94 6 695 698en_US
dc.identifier.citedreferenceSingh K. Xiao L. Remondino A. Sawyer D.B. Colucci W.S. Adrenergic regulation of cardiac myocyte apoptosis J. Cell. Physiol. 2001 189 3 257 265en_US
dc.identifier.citedreferenceKoobs D.H. Schultz R.L. Jutzky R.V. The origin of lipofuscin and possible consequences to the myocardium Arch. Pathol. Lab. Med. 1978 (Feb) 102 2 66 81en_US
dc.identifier.citedreferenceNakano M. Oenzil F. Mizuno T. Gotoh S. Age‐related changes in lipofuscin accumulation of brain and heart Gerontology 1995 41 Suppl. 2 69 79en_US
dc.identifier.citedreferenceScarabelli T.M. Stephanou A. Pasini E. et al. Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes during ischemia/reperfusion injury Circ. Res. 2002 90 745 748en_US
dc.identifier.citedreferenceScarabelli T. Stephanou A. Rayment N. et al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury Circulation 2001 104 253 256en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.